CSF Biomarker May Support Lewy Body Diagnosis - Scorecard - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

CSF Biomarker May Support Lewy Body Diagnosis

A multicohort analysis suggests cerebrospinal fluid DOPA decarboxylase may help distinguish dementia with Lewy bodies and Parkinson’s disease from Alzheimer’s disease and controls

  • By

  • Henry Thomas

  • April 3, 2026

  • 2 min

Share

Clinical Scorecard: CSF Biomarker May Support Lewy Body Diagnosis

At a Glance

CategoryDetail
ConditionLewy body disorders (e.g., Parkinson’s disease, dementia with Lewy bodies)
Key MechanismsElevated cerebrospinal fluid (CSF) levels of DOPA decarboxylase (DDC)
Target PopulationPatients with Lewy body disorders, Alzheimer’s disease, and cognitively healthy controls
Care SettingClinical and research settings

Key Highlights

  • CSF DDC levels higher in Lewy body disorders than in controls and Alzheimer’s disease
  • Strong diagnostic performance when incorporating CSF DDC, age, and sex
  • No diagnostic value found for plasma DDC
  • Higher CSF DDC levels associated with parkinsonian symptoms and visual hallucinations
  • Reflects disease-related changes in affected brain regions

Guideline-Based Recommendations

Diagnosis

  • Use CSF DDC levels to support differential diagnosis of Lewy body disorders

Management

  • Further studies needed to evaluate performance across broader patient populations

Monitoring & Follow-up

  • Monitor CSF DDC levels in relation to clinical features of dementia with Lewy bodies

Risks

  • Potential relationships with industry reported by study authors

Patient & Prescribing Data

Patients with Lewy body disorders and Alzheimer’s disease

Higher CSF DDC levels observed primarily in patients receiving dopaminergic therapy

Clinical Best Practices

  • Incorporate CSF DDC measurements in diagnostic evaluations
  • Consider clinical features when interpreting CSF DDC levels

Related Resources & Content

Original Source(s)

CSF Biomarker May Support Lewy Body Diagnosis

  • by Henry Thomas

  • April 3, 2026

Related Content

Top 10 Evidence-Based Essentials in Neurology

A structured framework of guidelines, trials, therapies, and tools used in clinical practice.

Diet-Dementia Link Varies by Biomarkers

Effects varied by which biomarker and diet were measured, and the study stops short of proving diet changes risk.

Side Effects: Sour Mouth, Lower BP

Acidic gum beat sugar-free at cranking out nitric oxide from beetroot juice — exactly backward from what test-tube studies predicted. Also this week: a sleep gene that ignores amyloid, and jackfruit sap moonlighting as a bone-building drug delivery system.